Barmah forest virus disease
disease diseaseOn this page
Also known as Barmah Forest virus caused disease or disorderBarmah Forest virus disease or disorderBarmah Forest virus infectious disease
Summary
Barmah forest virus disease (MONDO:0000343) is a disease. A subtype of Alphavirus infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Barmah forest virus disease |
| Mondo ID | MONDO:0000343 |
| DOID | DOID:0050517 |
| GARD | 0027521 |
| Is cancer (heuristic) | no |
Also known as: Barmah Forest virus caused disease or disorder · Barmah Forest virus disease or disorder · Barmah Forest virus infectious disease
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Togaviridae infectious disease › Alphavirus infectious disease › Barmah forest virus disease
Related subtypes (5): O’nyong’nyong fever, Ross river fever, Venezuelan equine encephalitis, chikungunya, western equine encephalitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.